Management remarks
Call period: 2026 Q2 · 2026-08-03
Demand and orders: Charles Wagner: CF revenue grew 9% year-over-year, led by strong volume growth from ALYFTREK uptake, continued performance from TRIKAFTA and higher realized net price. Outside the U.S., CF revenue grew 12% year-over-year, driven by strong ALYFTREK launches, timing of orders in certain geographies as well as the benefit from FX.Margins: Charles Wagner: As our new products, particularly CASGEVY, increase in revenue contribution with higher cost of goods sold than our small-molecule CF products, we continue to expect full year gross margin of just under 86%, roughly in line with this quarter's result.Analyst Q&A
Analyst Salveen Richter asked: Two for me. One is you announced that the Phase II/III OLYMPUS study for Pove in pMN is going to move to Phase III with an 80-milligram dose every 4 weeks. Can you frame what signal this was based on and whether you or the DSMB or what you or the DSMB saw on the Phase IIb portion to move forward? Management Reshma Kewalramani answered: The DSMB was asked to base their decision and it was their decision because we do not have access to the unblinded data to look at on efficacy PLA2R, which is the biomarker equivalent in membranous as Gd-IgA1 is to IgAN. Of course, they had full access to the safety results as they made their decision. I suppose in many ways, it's not surprising that they picked the 80-milligram dose given the RUBY-3 results, where you could see that the 80 milligrams had a very nice reduction in PLA2R, but that's how the decision was made.管理层陈述
电话会期间：2026 Q2 · 2026-08-03
需求与订单：查尔斯·瓦格纳：受ALYFTREK销量强劲增长、TRIKAFTA持续表现良好以及实际净价格提升推动，CF业务营收同比增长9%。美国以外地区CF业务营收同比增长12%，得益于ALYFTREK上市表现强劲、部分地区订单的时间安排以及外汇收益利好。利润率：查尔斯·瓦格纳：随着新产品（尤其是CASGEVY）的营收贡献增加，且其销售成本高于我们的小分子CF产品，我们仍预计全年毛利率略低于86%，与本季度结果大致相符。分析师问答
分析师萨尔文·里希特提问：你们宣布针对pMN的Pove的II/III期OLYMPUS研究将推进至III期，剂量为每4周80毫克，请问该决定基于什么信号，是你们还是DSMB在IIb阶段观察到相关结果后作出推进决定的？管理层成员雷斯玛·凯瓦尔拉马尼回答：最终决定由DSMB作出，因我们无法获取PLA2R疗效的未盲化数据，而DSMB可完全获取安全性结果。鉴于RUBY-3试验中80毫克剂量可显著降低PLA2R水平，该选择并不意外，此决定即基于这些因素作出。This earnings research was prepared from company results, regulatory filings, financial statements, and earnings-call transcripts or official replays. It is for informational purposes only and does not constitute investment advice.这篇财报研究基于公司业绩公告、监管文件、财务报表，以及财报电话会议记录或官方回放整理。内容仅供参考，不构成投资建议。
